Search the Newsreel

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

Enterprise value to EBIT forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This article provides financial data for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to EBIT forward ratio. The content appears to be a snapshot from a financial data platform, indicating market status and offering various tools and resources.

Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA

Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Mobia Medical, Inc. (NASDAQ:MOBI) Given Average Recommendation of "Moderate Buy" by Analysts

Number of shareholders of Twareat Medical Care Co. – TADAWUL:9627

ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Moderate Buy" by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received a "Moderate Buy" consensus rating from nine analysts, with an average 12-month price target of $192.80. The company recently surpassed quarterly earnings and revenue expectations, reporting $2.37 EPS on $547.88 million in revenue, and provided fiscal 2026 EPS …

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ionis Pharmaceuticals, Inc., providing detailed financial metrics for each fund. The ETFs are sorted by market value and include information such as weight of Ionis stock, issuer, management style, expense ratio, assets …

Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS

Empowered Funds LLC significantly increased its stake in Ionis Pharmaceuticals, Inc. during the first quarter, now holding over 103,000 shares valued at $7.75 million. Institutional investors collectively own 93.86% of the company, while insiders have sold a substantial amount of shares. Despite recent price …

Empowered Funds LLC Buys 16,525 Shares of Alpha Metallurgical Resources, Inc. $AMR

Empowered Funds LLC increased its stake in Alpha Metallurgical Resources, Inc. (NYSE:AMR) by 79.4% in the first quarter, adding 16,525 shares and bringing its total holdings to 37,347 shares valued at approximately $7.7 million. Other institutional investors also adjusted their positions in AMR, which …

Bank Hapoalim BM Invests $2.67 Million in Zscaler, Inc. $ZS

Bank Hapoalim BM recently acquired 18,885 shares of Zscaler, Inc. (NASDAQ:ZS) worth approximately $2.67 million during the second quarter. This investment is part of broader institutional interest, with several other large investors also increasing their stakes in the cloud security company. Despite recent analyst …

Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Assenagon Asset Management S.A. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 57,075 shares, decreasing its holdings by 73.1%. Despite this, other institutional investors have either increased their positions or acquired new ones in ACADIA Pharmaceuticals. Insider selling also occurred, with executives …

125,970 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 125,970 shares valued at approximately $62.52 million during the second quarter. Other hedge funds have also adjusted their holdings in the company, which is 90.96% owned by institutional investors. Vertex …

Inspire Medical Systems (INSP) Stock May Be Cheap After A 74% Fall

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Zscaler, Inc. (NASDAQ:ZS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Zscaler, Inc. (NASDAQ:ZS) has received a consensus "Moderate Buy" rating from analysts, with 34 out of 41 firms recommending to buy the stock. The average 12-month price target is set at $214.21, following recent quarterly results that surpassed expectations, reporting adjusted EPS of $1.08 …

Enterprise value to EBITDA forward of Professional Medical Expertise Co. – TADAWUL:9574

Helical Tightens Capital Structure with Treasury Share Buyback

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Orthofix (OFIX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief IR and Communications Officer - Julie Dewey President and Chief Executive Officer - Massimo Calafiore Chief Financial Officer - Julie Andrews Full Conference Call Transcript Operator: Thank …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Neuroone Medical earnings missed by $0.10, revenue fell short of estimates

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug

Madrigal Pharmaceuticals (MDGL) is attracting retail investor attention due to newly acquired U.S. patents for its lead liver disease drug, Rezdiffra, and ongoing speculation about a potential acquisition, possibly by Eli Lilly. Rezdiffra is Madrigal's sole marketed product, and the company is actively expanding …

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

Crinetics Pharmaceuticals (CRNX) recently reported its Q2 2026 results, showing US$25.12 million in revenue and a net loss of US$120.86 million. Despite the loss, the stock has seen significant price gains, with a 90-day return of 130.35% and a 1-year return of 175.72%. Analysts …

Price to book forward of Quoin Pharmaceuticals, Ltd. – NASDAQ:QNRX

The article displays the "Price to book forward" for Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) as provided by TradingView. It indicates that the market was closed and no trades were made at the time of publication. The content primarily focuses on financial data presentation within …

California Water Service Group Named a Top Workplace in USA for Second Consecutive Year

California Water Service Group has been recognized as a Top Workplace in the USA for the second consecutive year by Energage. This award is based on employee feedback gathered through an anonymous survey, highlighting the company's commitment to fostering an exceptional workplace culture. The …

Cal-Maine Foods: Depressed Egg Prices, Yet A Fundamentally Stronger Business

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical's updated outlook reflects a rebound in bone growth stimulation reimbursement and improved trends in biologics and limb reconstruction, partially offset by a steeper-than-expected decline among smaller U.S. spine distributors. The company expects third-quarter revenue to be similar to the second quarter with …

Eupraxia Pharmaceuticals (EPRX) Advances 0.75% as Price Approaches Key Resistance - Post-Earnings Moves